Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ZVSA

ZyVersa Therapeutics Inc

May 06 • 04:00PM ET

6.39

Dollar change +0.94
Percentage change 17.25	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-71.31	Insider Own	1.17%	Shs Outstand	0.76M	Perf Week	10.75%
Market Cap	4.86M	Forward P/E	-	EPS next Y	-46.20	Insider Trans	0.00%	Shs Float	0.75M	Perf Month	-12.90%
Income	-106.25M	PEG	-	EPS next Q	-3.70	Inst Own	13.75%	Short Float	6.14%	Perf Quarter	4.75%
Sales	0.00M	P/S	-	EPS this Y	98.62%	Inst Trans	-	Short Ratio	0.12	Perf Half Y	-81.12%
Book/sh	27.33	P/B	0.23	EPS next Y	-206.98%	ROA	-139.81%	Short Interest	0.05M	Perf Year	-96.80%
Cash/sh	4.13	P/C	1.55	EPS next 5Y	-	ROE	-177.00%	52W Range	4.44 - 220.85	Perf YTD	-29.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-959.37%	52W High	-97.11%	Beta	0.68
Dividend TTM	-	Quick Ratio	0.33	Sales past 5Y	0.00%	Gross Margin	-	52W Low	43.92%	ATR (14)	0.88
Dividend Ex-Date	-	Current Ratio	0.33	EPS Y/Y TTM	-216.92%	Oper. Margin	0.00%	RSI (14)	50.49	Volatility	14.51% 12.90%
Employees	7	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	70.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-6291.81%	Payout	-	Rel Volume	1.30	Prev Close	5.45
Sales Surprise	-	EPS Surprise	-1342.72%	Sales Q/Q	-	Earnings	Mar 25 BMO	Avg Volume	394.64K	Price	6.39
SMA20	4.15%	SMA50	-15.36%	SMA200	-74.93%	Trades		Volume	514,655	Change	17.25%

Apr-29-24 07:57AM	ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's Disease (GlobeNewswire) +15.63%
Apr-04-24 07:57AM	ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes (GlobeNewswire)
Mar-25-24 08:17AM	ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-18-24 07:57AM	ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease (GlobeNewswire) +8.79%
Mar-14-24 07:57AM	ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled Inflammation Illuminated, at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024 (GlobeNewswire)
07:57AM	Loading…
Feb-29-24 07:57AM	ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity (GlobeNewswire) +10.00%
Feb-28-24 07:57AM	ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications (GlobeNewswire) -8.26%
Feb-26-24 07:55AM	Why Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today? (InvestorPlace) +34.83%
Feb-22-24 07:47AM	ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option (GlobeNewswire)
Feb-14-24 07:53AM	ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases (GlobeNewswire)
Feb-07-24 08:02AM	ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones (GlobeNewswire)
Jan-31-24 07:57AM	ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes (GlobeNewswire) -7.30%
Jan-24-24 07:57AM	ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer's Disease (GlobeNewswire) +5.67%
Jan-17-24 01:31PM	Why Is Inflammatory Disease-Focused ZyVersa Therapeutics Stock Trading Higher Today? (Benzinga)
07:52AM	ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis (GlobeNewswire)
08:06AM	Loading…
Jan-10-24 08:06AM	ZyVersa Therapeutics' CEO, Stephen C. Glover, Featured on Benzinga All Access (GlobeNewswire)
Jan-04-24 07:50AM	ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets (GlobeNewswire)
Jan-03-24 08:07AM	ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024 (GlobeNewswire)
Dec-18-23 08:12AM	ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During J.P. Morgan Week 2024 (GlobeNewswire) +38.06%
Dec-14-23 07:01AM	ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200 (GlobeNewswire)
Dec-07-23 11:20AM	ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes (GlobeNewswire) -46.26%
09:07AM	Why Is ZyVersa Therapeutics (ZVSA) Stock Down 44% Today? (InvestorPlace)
Dec-06-23 09:00PM	ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering (GlobeNewswire)
09:54AM	Why Is ZyVersa Therapeutics (ZVSA) Stock Up 27% Today? (InvestorPlace)
07:20AM	ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100's Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways (GlobeNewswire)
Nov-30-23 11:30AM	ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock (GlobeNewswire) -30.85%
Nov-14-23 04:35PM	ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results (GlobeNewswire) -9.68%
Nov-09-23 07:35AM	ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model (GlobeNewswire)
Nov-06-23 07:05AM	ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation (GlobeNewswire)
Nov-01-23 08:07AM	ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection (GlobeNewswire) +9.12%
06:50AM	Loading…
Oct-25-23 06:50AM	ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100's Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease (GlobeNewswire)
Oct-18-23 07:05AM	ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function (GlobeNewswire)
Oct-11-23 07:05AM	ZyVersa Therapeutics Announces Peer-Reviewed Publication in Nature Reviews Nephrology Substantiating VAR 200's Rationale for Mediating Transport of Cholesterol and Lipids Out of Kidney Cells to Attenuate Progression of Kidney Disease (GlobeNewswire) +10.40%
Oct-04-23 07:05AM	ZyVersa Therapeutics Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues (GlobeNewswire) -6.47%
Sep-27-23 07:07AM	ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in Panel at the BioFlorida Conference Discussing Inflammation and its Impact on Numerous Diseases (GlobeNewswire)
Sep-22-23 06:35AM	ZyVersa Therapeutics Announces Research Published in The Journal of Clinical Investigation Reinforcing IC 100s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues (GlobeNewswire)
Sep-12-23 06:30AM	ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100s Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases (GlobeNewswire) +15.45%
Aug-21-23 04:15PM	ZyVersa Therapeutics Reports Second Quarter 2023 Corporate and Financial Results (GlobeNewswire)
Jul-24-23 08:00AM	ZyVersa Therapeutics, Inc. Announces Pricing of $2.1 Million Public Offering (GlobeNewswire) -11.79%
Jul-17-23 07:38AM	ZyVersa Therapeutics Announces Publication in the Journal, Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18 in Development of Liver Fibrosis (GlobeNewswire)
Jul-14-23 07:37AM	ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 2nd Annual Kidney Conference to be Held Virtually on July 25, 2023 (GlobeNewswire)
Jul-10-23 07:37AM	ZyVersa Therapeutics Announces Publication in the Journal Circulation That Demonstrates the Role of Inflammasome Activation in Hypertrophic Heart Disease Induced by Mechanical Stress (GlobeNewswire)
Jul-07-23 07:37AM	European Patent Granted for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease (GlobeNewswire) +8.25%
Jun-28-23 07:37AM	ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal NLRP3 Inflammasome Activation and Lupus Nephritis Disease Activity (GlobeNewswire)
Jun-20-23 04:07PM	ZyVersa Therapeutics Announces a Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arteries of Patients with Peripheral Arterial Disease (PAD) (GlobeNewswire) -11.79%
Jun-13-23 08:07AM	ZyVersa Therapeutics Publishes New White Paper Detailing the Critical Role of Inflammasome ASC in Inflammatory Diseases, and Its Potential as a Therapeutic Target (GlobeNewswire)
Jun-06-23 09:07AM	European Patent Office to Grant ZyVersa Therapeutics Patent Application for Cholesterol Transport Mediator VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease (GlobeNewswire)
May-25-23 09:07AM	ZyVersa Therapeutics Announces a Publication in Frontiers in Medicine Showing Direct Inflammasome Activation in Children with Juvenile Idiopathic Arthritis (GlobeNewswire) -5.88%
May-19-23 04:15PM	ZyVersa Therapeutics Announces Changes to ZyVersas Board of Directors (GlobeNewswire) +14.23%
May-15-23 09:07AM	ZyVersa Therapeutics Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney Disease (GlobeNewswire) -6.00%
May-12-23 09:07AM	ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial Results (GlobeNewswire) -7.23%
May-11-23 09:07AM	ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in A.G.P.s Virtual Healthcare Conference (GlobeNewswire)
May-09-23 09:05AM	ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention (GlobeNewswire)
07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-04-23 09:07AM	ZyVersa Therapeutics Announces a Publication in Hepatology Revealing That Alcohol-induced Extracellular ASC Specks Perpetuate Liver Inflammation and Damage in Alcoholic Hepatitis (GlobeNewswire) +7.53%
May-01-23 06:30PM	ZyVersa Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering (GlobeNewswire) +13.02%
Apr-27-23 09:07AM	ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference (GlobeNewswire)
Apr-26-23 09:10AM	ZyVersa Therapeutics, Inc. Announces Pricing of $11.0 Million Public Offering (GlobeNewswire) -69.07%
Apr-25-23 09:07AM	ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinsons Disease (GlobeNewswire) -5.85%
Apr-24-23 09:07AM	ZyVersa Therapeutics Adds Dr. Douglas Golenbock to Its Inflammatory Disease Scientific Advisory Board to Support Advancement of Inflammasome ASC Inhibitor IC 100 (GlobeNewswire)
09:00AM	Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-19-23 09:07AM	ZyVersa Therapeutics Announces Article Published in Biomaterials Addressing the Critical Role of Inflammasome Activation in Neuroinflammation Resulting from Intracortical Implants (GlobeNewswire)
Apr-13-23 09:07AM	ZyVersa Therapeutics Announces Review Article Published in Frontiers in Pharmacology Addressing Microglial Inflammatory Activity as a Pharmacological Target in Mild Cognitive Impairment and Alzheimers Disease (GlobeNewswire)
Apr-12-23 09:07AM	ZyVersa Therapeutics CEO, Stephen C. Glover to Appear on Benzinga 'All Access' (GlobeNewswire)
Apr-11-23 09:07AM	ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Planet MicroCap Showcase (GlobeNewswire) -5.06%
Apr-10-23 09:07AM	ZyVersa Therapeutics Announces Article Published in Brain Pathology Addressing Inflammasome Signaling Proteins in Alzheimers Disease (GlobeNewswire)
Apr-03-23 09:05AM	ZyVersa Therapeutics Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results (GlobeNewswire)
Mar-13-23 04:30PM	ZyVersa Therapeutics Reports New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.67%
Mar-07-23 09:20AM	ZyVersa Therapeutics Adds Dr. Richard J. Glassock to Its Renal Scientific Advisory Board to Support Clinical Advancement of Renal Cholesterol Efflux Mediator VAR 200 (GlobeNewswire)
Mar-01-23 09:20AM	ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare Conference (GlobeNewswire)
Feb-27-23 09:20AM	ZyVersa Therapeutics to Participate in a Fireside Chat at Roth Annual Conference (GlobeNewswire)
Feb-23-23 09:20AM	ZyVersa Therapeutics Announces New Publication in Translational Research Showing IC 100 Reduces Inflammasome Activation in Mouse Model for Alzheimers Disease Following Traumatic Brain Injury (GlobeNewswire)
Jan-27-23 04:00PM	ZyVersa Therapeutics Reports Inducement Grant to Newly Appointed Chief Medical Officer Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-25-23 09:45AM	ZyVersa Therapeutics to Present at BIO CEO & Investor Conference (GlobeNewswire) -10.21%
Jan-11-23 02:45PM	ZyVersa Therapeutics CEO, Stephen C. Glover, to Present at the Virtual Investor 2023 Companies to Watch Event (GlobeNewswire) -9.91%
01:00PM	JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th (ACCESSWIRE)
Jan-05-23 09:45AM	ZyVersa Therapeutics Appoints Three New Board Members (PR Newswire)
Jan-03-23 09:45AM	ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200 (PR Newswire) +10.19%

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZVSA

ZyVersa Therapeutics Inc

Upgrade your FINVIZ experience